PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-100.00%
Revenue decline while GNPX shows 0.00% growth. Joel Greenblatt would examine competitive position erosion.
-100.00%
Both companies reducing costs. Martin Whitman would check industry efficiency trends.
100.00%
Similar gross profit growth to GNPX's 99.98%. Walter Schloss would investigate industry dynamics.
100.00%
Margin change of 100.00% while GNPX shows flat margins. Bruce Berkowitz would examine quality advantage.
7.04%
R&D growth less than half of GNPX's 60.00%. David Dodd would verify if efficiency advantage is sustainable.
-5.63%
G&A reduction while GNPX shows 13.17% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.59%
Operating expenses growth less than half of GNPX's 35.91%. David Dodd would verify sustainability.
2.59%
Total costs growth less than half of GNPX's 35.91%. David Dodd would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
13.04%
D&A growth while GNPX reduces D&A. John Neff would investigate differences.
-2.44%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-2.59%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-15.06%
Other expenses reduction while GNPX shows 11.12% growth. Joel Greenblatt would examine advantage.
-3.66%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Tax expense growth 1.1-1.25x GNPX's 81.00%. Bill Ackman would demand explanation.
-10.34%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-10.26%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-10.26%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
0.08%
Share count reduction exceeding 1.5x GNPX's 2.91%. David Dodd would verify capital allocation.
0.08%
Diluted share reduction exceeding 1.5x GNPX's 2.95%. David Dodd would verify capital allocation.